Nuvalent (NUVL) – Investment Analysts’ Recent Ratings Changes

Nuvalent (NASDAQ: NUVL) has recently received a number of price target changes and ratings updates:

• 6/3/2026 – Nuvalent was given a new $165.00 price target by Leerink Partners.
• 6/2/2026 – Nuvalent had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 5/28/2026 – Nuvalent had its “outperform” rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.
• 5/21/2026 – Nuvalent is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $189.00 price target on the stock.
• 5/21/2026 – Nuvalent is now covered by Sanford C. Bernstein. They set an “outperform” rating and a $189.00 price target on the stock.
• 5/21/2026 – Nuvalent was upgraded by Sanford C. Bernstein to “strong-buy”.
• 4/21/2026 – Nuvalent had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/21/2026 – Nuvalent had its “buy” rating reaffirmed by HC Wainwright. They now have a $155.00 price target on the stock.
• 4/8/2026 – Nuvalent had its “outperform” rating reaffirmed by Wedbush. They now have a $125.00 price target on the stock.

Insider Transactions at Nuvalent

In other Nuvalent news, CEO James Richard Porter sold 30,000 shares of the business’s stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $101.69, for a total transaction of $3,050,700.00. Following the completion of the sale, the chief executive officer owned 324,879 shares of the company’s stock, valued at approximately $33,036,945.51. The trade was a 8.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Henry E. Pelish sold 3,093 shares of the company’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $104.48, for a total value of $323,156.64. Following the sale, the insider owned 65,604 shares of the company’s stock, valued at $6,854,305.92. This represents a 4.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 96,953 shares of company stock worth $9,956,364 over the last ninety days. 5.02% of the stock is owned by insiders.

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.